{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:51:56Z","timestamp":1791255116360,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cjca.2025.12.060","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:44:58Z","timestamp":1768376698000},"page":"867-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Care for Patients With Elevated Lipoprotein(a) Level in Canada: A Practical Framework for Screening, Risk Assessment, and Management"],"prefix":"10.1016","volume":"42","author":[{"given":"George","family":"Thanassoulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit J.","family":"Arsenault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Bainey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam R.","family":"Brunham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Iatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlys L.","family":"Koschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamir R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Shekhar","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen J.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2025.12.060_bib1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global effect of modifiable risk factors on cardiovascular disease and mortality","volume":"389","author":"Magnussen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.12.060_bib3","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2025.12.060_bib5","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cjca.2025.12.060_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4068\/cmj.2021.57.1.36","article-title":"Recent updates of lipoprotein(a) and cardiovascular disease","volume":"57","author":"Liu","year":"2021","journal-title":"Chonnam Med J"},{"key":"10.1016\/j.cjca.2025.12.060_bib7","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.3390\/jcm11206040","article-title":"Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies","volume":"11","author":"Bhatia","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib8","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1042\/BCJ20240037","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"481","author":"Boffa","year":"2024","journal-title":"Biochem J"},{"key":"10.1016\/j.cjca.2025.12.060_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2025.110929","article-title":"Lp(a): a clinical review","volume":"137","author":"Anchouche","year":"2025","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cjca.2025.12.060_bib10","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2025.12.060_bib11","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.060_bib12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC Review Topic of the Week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033654","article-title":"Genetics and pathophysiological mechanisms of lipoprotein(a)-associated cardiovascular risk","volume":"13","author":"Volgman","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.12.060_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","article-title":"Oxidized phospholipid modification of lipoprotein(a): epidemiology, biochemistry and pathophysiology","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2025.12.060_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2025.100820","article-title":"Lipoprotein (a) integrates monocyte-mediated thrombosis and inflammation in atherosclerotic cardiovascular disease","volume":"66","author":"Rosenson","year":"2025","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cjca.2025.12.060_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","article-title":"Lipoprotein(a), platelet function and cardiovascular disease","volume":"21","author":"Bhatia","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib20","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib21","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2025.12.060_bib22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib23","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2022.09.021","article-title":"Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease","volume":"80","author":"Hedegaard","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0140-6736(00)02502-2","article-title":"Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)","volume":"356","author":"Anand","year":"2000","journal-title":"Lancet"},{"issue":"12_suppl","key":"10.1016\/j.cjca.2025.12.060_bib25","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/S0735-1097(25)03026-8","article-title":"Variation in lipoprotein(a) levels by place of birth worldwide: a population-based cross-sectional study (abstract)","volume":"85","author":"Lu","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in Black and White subjects","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.060_bib27","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.12.060_bib28","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.12.060_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.12.060_bib30","first-page":"397","article-title":"Lipoprotein(a) is a prevalent yet vastly underrecognized risk factor for cardiovascular disease","volume":"12","author":"Rendler","year":"2024","journal-title":"Health Care Curr Rev"},{"key":"10.1016\/j.cjca.2025.12.060_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120458","article-title":"Characterization of lipoprotein (a) testing in Alberta, Canada: a retrospective cohort study","volume":"408","author":"Manivong","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2025.12.060_bib32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jacc.2023.11.015","article-title":"Racial and ethnic disparities in perioperative health care among patients undergoing cardiac surgery: JACC State-of-the-Art Review","volume":"83","author":"Milam","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib33","doi-asserted-by":"crossref","unstructured":"Iatan I, Koschinsky ML, Trenaman L, et al. Rationale for the routine screening of lipoprotein (a) in cardiovascular risk assessment [e-pub ahead of print]. Eur J Prev Cardiol https:\/\/doi.org\/10.1093\/eurjpc\/zwaf342.","DOI":"10.1093\/eurjpc\/zwaf342"},{"key":"10.1016\/j.cjca.2025.12.060_bib34","article-title":"Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis","volume":"392","author":"Morton","year":"2025","journal-title":"Atherosclerosis"},{"issue":"suppl 8","key":"10.1016\/j.cjca.2025.12.060_bib35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.16469","article-title":"Why, how and in whom should we measure levels of lipoprotein(a): a review of the latest evidence and clinical implications","volume":"27","author":"Razavi","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cjca.2025.12.060_bib36","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1093\/eurheartj\/ehad547","article-title":"Significance of lipids, lipoproteins, and apolipoproteins during the first 14-16 months of life","volume":"44","author":"Taageby Nielsen","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.12.060_bib37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen General Population study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2025.12.060_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead035","article-title":"Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up","volume":"3","author":"Ziogos","year":"2023","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.cjca.2025.12.060_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2022.01.058","article-title":"The trajectory of lipoprotein(a) during the peri- and early postinfarction period and the impact of proprotein convertase subtilisin\/kexin type 9 inhibition","volume":"171","author":"Vavuranakis","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib40","article-title":"Changes in lipoprotein(a) concentrations in patients with acute coronary syndrome","volume":"135","author":"Sata\u0142a","year":"2025","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115531","article-title":"Changes in lipoprotein(a) levels in people after ST elevation myocardial infarction-the STEMI-Lipids Study","volume":"24","author":"Sourij","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2025.12.060_bib42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4330\/wjc.v16.i6.329","article-title":"Initial decrease in the lipoprotein(a) level is a novel prognostic biomarker in patients with acute coronary syndrome","volume":"16","author":"Saeki","year":"2024","journal-title":"World J Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2022.04.004","article-title":"Lipoprotein(a): an underestimated inflammatory mastermind","volume":"349","author":"Dzobo","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2025.12.060_bib44","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2025.04.013","article-title":"Lipoprotein(a), cholesterol, triglyceride levels, and vulnerable coronary plaques: a PROSPECT II substudy","volume":"85","author":"Erlinge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib45","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib46","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.CIR.0000159263.50305.BD","article-title":"Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas heart study","volume":"111","author":"Guerra","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.060_bib47","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/eurjpc\/zwae043","article-title":"The association of lipoprotein(a) and coronary artery calcium in asymptomatic patients: a systematic review and meta-analysis","volume":"31","author":"Martignoni","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","article-title":"Association of lipoprotein(a) with atherosclerotic plaque progression","volume":"79","author":"Kaiser","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib49","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1194\/jlr.P030890","article-title":"Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions","volume":"53","author":"Van Dijk","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cjca.2025.12.060_bib50","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.123.016152","article-title":"Lipoprotein(a) and coronary plaque in asymptomatic individuals: the Miami Heart Study at Baptist Health South Florida","volume":"17","author":"Mszar","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2025.12.060_bib52","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/CIRCULATIONAHA.116.026103","article-title":"A replicated, genome-wide significant association of aortic stenosis with a genetic variant for lipoprotein(a): meta-analysis of published and novel data","volume":"135","author":"Cairns","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.060_bib53","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2019.1581","article-title":"Genetic variation in LPA, calcific aortic valve stenosis in patients undergoing cardiac surgery, and familial risk of aortic valve microcalcification","volume":"4","author":"Perrot","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib55","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/eurheartj\/ehad142","article-title":"Dyslipidemia, inflammation, calcification, and adiposity in aortic stenosis: a genome-wide study","volume":"44","author":"Yu Chen","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.12.060_bib56","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamacardio.2024.1882","article-title":"Lipoprotein(a) and calcific aortic valve stenosis progression: a systematic review and meta-analysis","volume":"9","author":"Arsenault","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib57","article-title":"Impact of lipoprotein(a) on valvular and cardiovascular outcomes in patients with calcific aortic valve stenosis","volume":"14","author":"Girard","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.12.060_bib59","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.060_bib61","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jacc.2020.06.040","article-title":"Lipoprotein(a) and family history predict cardiovascular disease risk","volume":"76","author":"Mehta","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib63","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamacardio.2023.3548","article-title":"Concordance of a high lipoprotein(a) concentration among relatives","volume":"8","author":"Reeskamp","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2025.12.060_bib65","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life\u2019s Essential 8: updating and enhancing the American Heart Association\u2019s Construct of Cardiovascular Health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.060_bib66","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib67","first-page":"160","article-title":"Canadian Cardiovascular Society\/Canadian Association of Interventional Cardiology 2023 focused update of the guidelines for the use of antiplatelet therapy","volume":"40","author":"Bainey","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib68","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the Multi-Ethnic Study of Atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.12.060_bib69","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib70","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2025.12.060_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023578","article-title":"How do lipoprotein(a) concentrations affect clinical outcomes for patients with stable coronary artery disease who underwent different dual antiplatelet therapy after percutaneous coronary intervention?","volume":"11","author":"Cui","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.12.060_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100675","article-title":"Lipoprotein(a) and benefit of antiplatelet therapy: insights from the PEGASUS-TIMI 54 trial","volume":"2","author":"Patel","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.cjca.2025.12.060_bib73","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.060_bib74","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O\u2019Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib75","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.060_bib76","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.12.060_bib77","first-page":"197","article-title":"Lipoprotein apheresis","volume":"33","author":"Moriarty","year":"2015","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.cjca.2025.12.060_bib78","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib79","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib80","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(25)01391-1","article-title":"Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials","volume":"406","author":"Guo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.12.060_bib81","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1161\/CIRCIMAGING.113.000980","article-title":"Noncalcified coronary plaque volumes in healthy people with a family history of early onset coronary artery disease","volume":"7","author":"Kral","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2025.12.060_bib82","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.acra.2012.09.017","article-title":"Differences in coronary atherosclerotic plaque burden and composition according to increasing age on computed tomography angiography","volume":"20","author":"Choi","year":"2013","journal-title":"Acad Radiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib83","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib84","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib85","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib86","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41569-023-00860-8","article-title":"Novel and future lipid-modulating therapies for the prevention of cardiovascular disease","volume":"20","author":"Brandts","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib88","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib89","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.060_bib92","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib93","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib95","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran-A small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2025.12.060_bib97","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.060_bib99","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral Muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2025.12.060_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2025.12.060_bib101","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O\u2019Donoghue","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2025.12.060_bib102","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MOL.0000000000000982","article-title":"The need for national and international registries of patients with elevated lipoprotein(a)","volume":"36","author":"Kramer","year":"2025","journal-title":"Curr Opin Lipidol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:14:05Z","timestamp":1791252845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X26000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0828282X26000292"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2025.12.060","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Care for Patients With Elevated Lipoprotein(a) Level in Canada: A Practical Framework for Screening, Risk Assessment, and Management","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2025.12.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}